Table 1.
Characteristics of IA-AF and matched non-AF cohort at index day, and subgroups of IA-AF cohort according to antithrombotic therapy use .
| IA-AF cohort | Matched non-AF cohort | ||||
|---|---|---|---|---|---|
| Total | OAC ± AP b | AP only | Neither OACs nor AP | ||
| Total | 5555 | 2492 | 1603 | 1460 | 24705 |
| Agea mean ± SD | 70.9 ± 10.1 | 70.7 ± 9.0 | 73.8 ± 7.9 | 68.1 ± 12.9 | 70.9 ± 10.1 |
| Median age (IQR) | 73 (65,79) | 72 (66,77) | 75 (69,80) | 72 (60,79) | 73 (65,79) |
| Age ≥ 75 | 2407 (43.3) | 957 (38.4) | 871 (54.3) | 579 (39.7) | 10028 (43.3) |
| Female gender a | 2133 (38.4) | 863 (34.6) | 685 (42.7) | 585 (40.1) | 9582 (38.4) |
| BMI | 27.8 ± 5.3 | 28.3 ± 5.3 | 27.7 ± 5.4 | 27.1 ± 5.3 | 26.5 ± 4.5 |
| Current smoker | 652 (11.7) | 261 (10.5) | 180 (11.2) | 211 (14.5) | 3642 (14.4) |
| CHADS 2 a score, mean ± SD | 1.3 ± 1.1 | 1.3 ± 1.1 | 1.5 ± 1.1 | 1.0 ± 1.0 | 1.1 ± 1.1 |
| CHA 2 DS 2 VASc a score, mean ± SD | 2.5 ± 1.5 | 2.5 ± 1.5 | 2.9 ± 1.4 | 2.1 ± 1.5 | 2.3 ± 1.5 |
| Diabetes | 632 (11.4) | 301 (12.1) | 224 (14.0) | 107 (7.3) | 2450 (10.2) |
| Hypertension | 2984 (53.7) | 1391 (55.8) | 969 (60.4) | 624 (42.7) | 9565 (39.4) |
| CHF | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| MI | 232 (4.2) | 108 (4.3) | 79 (4.9) | 45 (3.1) | 1194 (5.0) |
| Coronary artery disease without MI | 590 (10.6) | 272 (10.9) | 235 (14.7) | 83 (5.7) | 2771 (11.5) |
| Stroke/TIA | 509 (9.2) | 242 (9.7) | 181 (11.3) | 86 (5.9) | 1474 (6.2) |
| Charlson score, mean ± SD | 0.94 ± 1.33 | 0.88 ± 1.23 | 1.10 ± 1.45 | 0.88 ± 1.35 | 0.87 ± 1.35 |
a Matching criteria. Patients with a history of CHF in the IA-AF and non-AF cohort were excluded. Data are presented as frequencies (percentages) unless otherwise stated. OAC: oral anticoagulants, AP: antiplatelets. IA-AF: incidentally detected ambulatory atrial fibrillation cohort; BMI: body mass index; CHF: congestive heart failure; IQR: interquartile range; MI: history of myocardial infarction; SD: standard deviation. Percentages for matched non-AF cohort weighted by the number of non-AF subjects matched to each IA-AF patient.
b OAC and AP use defined by any use within 180 days. OAC ± AP: includes 817 patients with use of OAC and AP in the 180 days following IA-AF.